<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>NSCLC treatment &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/nsclc-treatment/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 26 Nov 2023 20:18:04 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>NSCLC treatment &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Results of the MARIPOSA-2 Study for Advanced Lung Cancer</title>
		<link>https://bioengineer.org/results-of-the-mariposa-2-study-for-advanced-lung-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 26 Nov 2023 20:03:48 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[amivantamab therapy]]></category>
		<category><![CDATA[chemotherapy advancements]]></category>
		<category><![CDATA[EGFR mutations]]></category>
		<category><![CDATA[intracranial progression-free survival]]></category>
		<category><![CDATA[lazertinib effectiveness]]></category>
		<category><![CDATA[MARIPOSA-2 study]]></category>
		<category><![CDATA[NSCLC treatment]]></category>
		<category><![CDATA[osimertinib resistance]]></category>
		<category><![CDATA[personalized cancer care]]></category>
		<category><![CDATA[targeted therapy in lung cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=216965</guid>

					<description><![CDATA[The latest advancements in cancer treatment are offering new hope to patients with advanced non-small cell lung cancer (NSCLC), especially those with specific genetic mutations. This news report focuses on the MARIPOSA-2 study, an extensive global trial that investigates the effectiveness of new treatment combinations for NSCLC patients who have developed resistance to standard therapies. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">216965</post-id>	</item>
	</channel>
</rss>
